Edit
ChemoCentryx
https://www.chemocentryx.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 26.06.2026
Active
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We are dedicated to our patients and committed to delivering medications that meet unmet needs in the current therapeutic landscape.
Location: United States, California, San Carlos
Employees: 51-200
Phone: +1 650-210-2900
Total raised: $29.84M
Founded date: 1997
Investors 2
| Date | Name | Website |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.03.2007 | - | $29.84M | - |
Mentions in press and media 13
| Date | Title | Description |
| 26.06.2026 | CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union | Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal P... |
| 08.10.2021 | With FDA nod, ChemoCentryx pill stands out in a sea of injectable & infused meds | The mainstay treatments for autoimmune conditions still subject patients to needles, either injections or infusions. ChemoCentryx’s nearly 25-year quest to develop more convenient pill therapies for chronic conditions has finally paid off. ... |
| 28.09.2018 | UK biotech sees boost in biotech fundraising so far this year; ChemoCentryx kills plans for stock offer | → BIA and Informa Pharma Intelligence reported Friday that the UK biotech industry saw $2.05 billion in new fundraising in the first 8 months of this year — more than all of last year. That figure adds venture rounds with IPO... |
| 14.02.2012 | HBM BioVentures bringt Portfoliounternehmen erfolgreich an die Börse | |
| 06.01.2012 | GSK licenses ChemoCentryx arthritis treatment to bolster drug pipeline | GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, now takes over paying for any additional costs for clinical studies and commercialization of the drug. ChemoCentryx is eligible for additional payments based on... |
| 17.11.2008 | Cancer drug developer ChemoCentryx cancels IPO | Mountain View, Calif.-based biotech firm ChemoCentryx announced that it withdrew its filing to go public, citing (as per usual) unfavorable market conditions. The company, which develops drugs to treat cancer and autoimmune ailments like Cr... |
| 06.10.2008 | ChemoCentryx raises $50M, eyes bleak IPO landscape for biotech | ChemoCentryx Inc., a biotech company that develops drugs to treat immune system ailments, got a $50 million payday from partner and major shareholder GlaxoSmithKline PLC in August. The plan last November was to raise $57.5 million through a... |
| 13.11.2007 | Chemokine-drug maker ChemoCentryx files for $58M IPO | See our story about this Mountain View, Calif., biotech at VentureBeat Life Sciences. VentureBeat VentureBeat's mission is to be a digital townsquare for technical decision makers to gain knowledge about transformative technology and transa... |
| 12.11.2007 | IPOs: Biotech ChemoCentryx and specialty-pharma Xanodyne head for the public market | ChemoCentryx files for $58M IPO to fund autoimmune, inflammation drug — Mountain View, Calif.-based ChemoCentryx, a biotech focused on new small-molecule drugs that affect a class of biochemical signals known as chemokines, filed to raise $... |
| 22.03.2007 | ChemoCentryx, autoimmune disease drug co., raises $29.84M | ChemoCentryx, a Mountain View, Calif. developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has raised $29.84 million in forth round of funding, according to a regulatory filing cited by PE Week. Glaxo Group L... |
Show more